BIOFARMA GROUP
Acquired by
ARDIAN
BIOFARMA GROUP acquired by ARDIAN
Target
BIOFARMA GROUP
Acquirer
ARDIAN
Context
Ardian acquired a majority stake in Biofarma Group from White Bridge Investments. Ardian's entry is designed to transform the European leader into a global champion, specifically targeting expansion into the US and APAC markets while maintaining its technological lead in the high-margin probiotic segment.
BIOFARMA GROUP, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.4x average currently observed in the Healthcare & Pharma sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Biofarma Group is a leading European Contract Development and Manufacturing Organization (CDMO) for the nutraceutical and personal care industries. It specializes in the development, production, and packaging of food supplements, medical devices, probiotics, and cosmetics. The group is recognized for its high R&D capabilities and state-of-the-art production facilities.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with BIOFARMA GROUP
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.